Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:PPD

PPD (PPD) Stock Price, News & Analysis

PPD logo

About PPD Stock (NASDAQ:PPD)

Key Stats

Today's Range
$47.28
$47.28
50-Day Range
$47.10
$47.41
52-Week Range
$31.54
$47.41
Volume
N/A
Average Volume
1.91 million shs
Market Capitalization
$16.61 billion
P/E Ratio
47.28
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

PPD, Inc., together with its subsidiaries, provides drug development services to the biopharmaceutical industry worldwide. The company operates through two segments, Clinical Development Services and Laboratory Services. It offers clinical development services, including product development and consulting, early development, Phases II-IV clinical trial management, accelerated enrollment, peri-and post-approval, and medical communications services. The company also provides laboratory services comprising bioanalytical, biomarker, vaccine science, good manufacturing practice, and central laboratory services. It serves pharmaceutical, biotechnology, medical device, and government organizations, as well as other industry participants. The company has a collaboration with Science 37 to design, build, test, implement, and execute digital trials using Science 37's DCT SaaS-based technology platform. PPD, Inc. was founded in 1985 and is headquartered in Wilmington, North Carolina.

Receive PPD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PPD and its competitors with MarketBeat's FREE daily newsletter.

PPD Stock News Headlines

The Crypto That’s Making Wall Street Sweat
The Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech giants are quietly integrating it. Venture capitalists are scrambling to invest.
See More Headlines

PPD Stock Analysis - Frequently Asked Questions

PPD, Inc. (NASDAQ:PPD) issued its quarterly earnings results on Wednesday, October, 27th. The company reported $0.43 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.38 by $0.05. The firm's quarterly revenue was up 26.5% compared to the same quarter last year.

PPD (PPD) raised $1.5 billion in an IPO on Thursday, February 6th 2020. The company issued 60,000,000 shares at $24.00-$27.00 per share. Barclays, J.P. Morgan, Morgan Stanley, Goldman Sachs, BofA Securities, Credit Suisse, Jefferies, UBS Investment Bank, Citigroup, Deutsche Bank Securities, Evercore ISI, HSBC, Mizuho Securities, Baird and William Blair acted as the underwriters for the IPO and BofA Securities, Credit Suisse, Jefferies, UBS Investment Bank, Citigroup, Deutsche Bank Securities, Evercore ISI, HSBC, Mizuho Securities, Baird, William Blair and Drexel Hamilton were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that PPD investors own include Meta Platforms (META), Pfizer (PFE), NVIDIA (NVDA), Salesforce (CRM), Taiwan Semiconductor Manufacturing (TSM), Alibaba Group (BABA) and Advanced Micro Devices (AMD).

Company Calendar

Last Earnings
10/27/2021
Today
11/12/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Commercial Physical Research
Sub-Industry
N/A
Current Symbol
NASDAQ:PPD
Fax
N/A
Employees
26,000
Year Founded
N/A

Profitability

Net Income
$153.69 million
Pretax Margin
7.31%

Debt

Sales & Book Value

Annual Sales
$4.68 billion
Cash Flow
$1.99 per share
Book Value
($1.21) per share

Miscellaneous

Free Float
344,718,000
Market Cap
$16.61 billion
Optionable
Not Optionable
Beta
1.96
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

This page (NASDAQ:PPD) was last updated on 11/13/2024 by MarketBeat.com Staff
From Our Partners